Breast cancer drug not recommended for use in England

September 4, 2017, Cancer Research UK
Breast cancer drug not recommended for use in England
Credit: Cancer Research UK

The drug fulvestrant (Faslodex) has not been recommended in England to treat late stage breast cancer, in draft guidance.

The National Institute for Health and Care Excellence (NICE) has provisionally rejected fulvestrant for post-menopausal women with a form of the disease known as oestrogen-receptor positive.

Professor Arnie Purushotham, Cancer Research UK's senior clinical adviser, said that the decision was disappointing.

"Trials have shown that it can stall the 's growth, although the results don't yet show that it can improve survival," he said.

"We hope the manufacturer and NICE can work together to reach an agreement which allows the drug to be made available when NICE issues its final guidance."

The guidance covers women whose breast cancer is at a later stage or has spread to other parts of the body.

Fulvestrant works by blocking the hormone oestrogen, stopping its ability to cause some breast cancers to grow.

It would be used for postmenopausal women who haven't previously been treated with hormonal therapy such as aromatase inhibitors or tamoxifen.

Of the 32,000 diagnosed with breast cancer each year in England, it's estimated that up to 1,200 would be eligible for treatment with fulvestrant.

While NICE acknowledged that it can stall tumour growth by up to three months compared to , it said early evidence isn't strong enough to show that the drug extends survival.

A final decision will be made later in the year.

NICE said cheaper treatments are available which have more evidence for increasing survival.

The average cost of a course of fulvestrant is nearly £16,000.

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said that while better treatments are needed for advanced , NICE has to ensure that those treatments offer value for money.

"As fulvestrant has not been shown to be cost-effective, we can't justify diverting NHS funds from other areas of healthcare in order to fund its use," she added.

Explore further: Breast cancer drug approved for NHS England

More information: Fulvestrant for untreated hormone-receptor positive metastatic breast cancer [ID951]. www.nice.org.uk/guidance/indev … ltation/html-content

Related Stories

Breast cancer drug approved for NHS England

June 16, 2017
The drug trastuzumab emtansine (Kadcyla) will soon be routinely available for patients in England with an advanced type of breast cancer.

Adding everolimus to fulvestrant improved outcomes for postmenopausal patients with HR-positive breast cancer

December 8, 2016
Progression-free survival was more than doubled for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy by adding everolimus (Afinitor) to treatment ...

Targeting estrogen receptor improves progression-free survival in advanced breast cancer

October 8, 2016
Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO ...

Anastrozole and fulvestrant combo better than single drug for metastatic breast cancer

August 1, 2012
Results of a SWOG clinical trial published August 2 in the New England Journal of Medicine show the combination of anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metastatic ...

New drug combination for advanced breast cancer delays disease progression

December 10, 2014
A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The findings of the randomized study (S6-03) ...

New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy

September 26, 2011
Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome. Researchers ...

Recommended for you

Daily low-dose aspirin may be weapon against ovarian cancer

July 20, 2018
(HealthDay)— One low-dose aspirin a day could help women avoid ovarian cancer or boost their survival should it develop, two new studies suggest.

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

High fruit and vegetable consumption may reduce risk of breast cancer, especially aggressive tumors

July 19, 2018
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.